<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00719160</url>
  </required_header>
  <id_info>
    <org_study_id>0408026977</org_study_id>
    <nct_id>NCT00719160</nct_id>
  </id_info>
  <brief_title>The Effect of Protein on Calcium Absorption and Gastric Acid Production</brief_title>
  <official_title>Dietary Protein's Effect on Gastric pH and Calcium Absorption</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We have established that dietary protein is an important regulator of intestinal calcium
      absorption in humans. However, we do not understand the mechanism by which dietary protein is
      affecting calcium absorption. Therefore, the purpose of this research is to evaluate whether
      dietary protein-induced changes in gastric acid secretion explain the observed changes in
      intestinal calcium absorption.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We have established that dietary protein is an important regulator of intestinal calcium
      absorption in humans. However, we do not understand the mechanism by which dietary protein is
      affecting calcium absorption. Therefore, the purpose of this research is to evaluate whether
      dietary protein-induced changes in gastric acid secretion explain the observed changes in
      intestinal calcium absorption. We have compelling in vitro data that amino acids can
      stimulate gastric acid secretion. We have found that this occurs via allosteric activation of
      the calcium sensing receptor expressed on the gastric acid-secreting parietal cells. At a
      fixed concentration of extracellular calcium, addition of L but not D isomers of specific
      amino acids activates the calcium sensing receptor and stimulates parietal cell acid
      production. We hypothesize that dietary protein induced gastric acid production increases
      calcium solubility and bioavailability thereby increasing its absorption. We will test this
      hypothesis in humans by quantifying the impact of dietary protein on intestinal calcium
      absorption in subjects who cannot make gastric acid. We will measure intestinal calcium
      absorption in healthy adults as they consume either a high protein diet with concomitant
      administration of a proton pump inhibiting (PPI) drug or the same high protein diet with a
      placebo instead of a PPI. The order of the 2 interventions will be randomized, and study will
      be double-blind and placebo controlled. If our hypothesis is correct, then intestinal calcium
      absorption will be highest during the high protein diet with placebo, and lowest during the
      drug intervention.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Intestinal Calcium Absorption</measure>
    <time_frame>Day 5 of a high protein diet</time_frame>
    <description>This is completed by measuring the amount of calcium absorbed by utilizing dual stable calcium isotopes. It was hypothesized that we would see a percent decrease as a result of the proton pump inhibitor. Previous published data indicated a decline in calcium absorption of 6.6 +/- 5.5% when gastric pH is blocked.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastric pH</measure>
    <time_frame>Day 5 of a high protein diet</time_frame>
    <description>The American Heritage Dictionary defines pH as &quot;a measure of the acidity or alkalinity of a solution, numerically equal to 7 for neutral solutions, increasing with increasing alkalinity and decreasing with increasing acidity. The pH scale commonly in use ranges from 0 to 14.&quot; The normal pH range for stomach acid is between 1.5 and 3.5.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Esomeprazole</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>esomeprazole</intervention_name>
    <description>2 Interventions with esomeprazole 20 mg twice a day for 9 days vs. a placebo for 9 days while on a high protein diet</description>
    <arm_group_label>Esomeprazole</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 20 mg twice a day for 9 days</description>
    <arm_group_label>Esomeprazole</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men and women age 18-45 years

          -  Caucasian or Asian descent due to increased risk of Osteoporosis

        Exclusion Criteria:

          -  gastrointestinal diseases

          -  osteoporosis

          -  diabetes

          -  hypertension

          -  liver disease

          -  thyroid disorders

          -  kidney disease

          -  kidney stones

          -  cancer

          -  heart disease

          -  eating disorders

          -  obesity

          -  hypogonadism

          -  amenorrhea

          -  oligomenorrhea

          -  abnormal serum FSH or estradiol levels

          -  birth control medication or other hormone-altering medications

          -  pregnancy

          -  Lifestyle factors such as:

               -  smoking

               -  excessive exercise (although moderate exercise is allowed)

               -  prescription medications known to influence vitamin D or calcium metabolism or
                  gastric acid

               -  excessive body weight change during the past 6 months

               -  food allergies

               -  unusual eating habits or medically prescribed diets
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl Insogna, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale New Haven Hospital Hospital Research Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2008</study_first_submitted>
  <study_first_submitted_qc>July 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2008</study_first_posted>
  <results_first_submitted>January 26, 2012</results_first_submitted>
  <results_first_submitted_qc>November 30, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 4, 2013</results_first_posted>
  <last_update_submitted>November 30, 2012</last_update_submitted>
  <last_update_submitted_qc>November 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Karl Insogna</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Gastric acid</keyword>
  <keyword>Dietary protein</keyword>
  <keyword>Calcium</keyword>
  <keyword>Intestinal absorption</keyword>
  <keyword>Calcium sensing receptor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>12 healthy women and men enrolled</recruitment_details>
      <pre_assignment_details>Participants received either Esomeprazole or placebo first and then crossed over to receive the other intervention with a minimum 2 week washout in-between.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Intervention Esomeprazole First/Placebo Second</title>
          <description>In this group this group received the intervention first and then the placebo</description>
        </group>
        <group group_id="P2">
          <title>Intervention Placebo First/Esomeprazole Second</title>
          <description>In this group this group received the placebo first and then the intervention</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>Includes groups randomized to receive 20 mg twice daily of either placebo or esomeprazole first</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.9" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Intestinal Calcium Absorption</title>
        <description>This is completed by measuring the amount of calcium absorbed by utilizing dual stable calcium isotopes. It was hypothesized that we would see a percent decrease as a result of the proton pump inhibitor. Previous published data indicated a decline in calcium absorption of 6.6 +/- 5.5% when gastric pH is blocked.</description>
        <time_frame>Day 5 of a high protein diet</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole</title>
            <description>Esomeprazoled administered twice daily in either first or second intervention period</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered twice daily in either first or second intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Intestinal Calcium Absorption</title>
          <description>This is completed by measuring the amount of calcium absorbed by utilizing dual stable calcium isotopes. It was hypothesized that we would see a percent decrease as a result of the proton pump inhibitor. Previous published data indicated a decline in calcium absorption of 6.6 +/- 5.5% when gastric pH is blocked.</description>
          <units>percentage of calcium absorption</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.2" spread="2.4"/>
                    <measurement group_id="O2" value="31.5" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gastric pH</title>
        <description>The American Heritage Dictionary defines pH as &quot;a measure of the acidity or alkalinity of a solution, numerically equal to 7 for neutral solutions, increasing with increasing alkalinity and decreasing with increasing acidity. The pH scale commonly in use ranges from 0 to 14.&quot; The normal pH range for stomach acid is between 1.5 and 3.5.</description>
        <time_frame>Day 5 of a high protein diet</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole Study Drug</title>
            <description>Esomeprazole 20 mg twice daily given as either the first or second intervention</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 20 mg twice a day given as either the first or second intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Gastric pH</title>
          <description>The American Heritage Dictionary defines pH as &quot;a measure of the acidity or alkalinity of a solution, numerically equal to 7 for neutral solutions, increasing with increasing alkalinity and decreasing with increasing acidity. The pH scale commonly in use ranges from 0 to 14.&quot; The normal pH range for stomach acid is between 1.5 and 3.5.</description>
          <units>units on a scale of pH</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.38" spread="0.13"/>
                    <measurement group_id="O2" value="2.70" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Entire Study Population</title>
          <description>Includes groups randomized to receive 20 mg twice daily of either placebo or esomeprazole first</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Karl L. Insogna, M.D.</name_or_title>
      <organization>Yale University</organization>
      <phone>203-737-2871</phone>
      <email>Karl.insogna@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

